Маргарита Павловна Заикина

Маргарита Павловна Заикина

Auto-generated profile, based on publicly available information

Маргарита Павловна Заикина

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Health Care of the Russian Federation
Verified
Journal Article
Closed access
PDF file
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
VKValentina Kapustina
Valentina Kapustina
SSStanislav I. Savel'EV
Stanislav I. Savel'EV
ССС. И. Савельев
С. И. Савельев
Obesity and overweight are severe problems in modern life. Research, clinical guidelines, and reviews present obesity as an adverse prognostic factor for cardiovascular disease and diabetes. However, there is growing evidence that an increased body mass index can be a prognostically favorable factor for some conditions. A lot of such works are related to diseases for which increased body weight is the most significant risk factor. This phenomenon has been called the “obesity paradox”. Although many studies show this paradox, there are no specific pathogenic mechanisms that could confirm this phenomenon. The research leaves more questions than answers. This review contains their analysis in the following nosologies: arterial hypertension, coronary artery disease, heart failure, diabetes mellitus type 2. The objectives of this study are to identify problems with existing research and find ways to explain the obesity paradox. A literature search was carried out on the databases of PubMed. To assess the problems of modern research, clinical studies were analyzed. To find the causes of this paradox, literature reviews were examined. The obesity paradox has been confirmed in heart failure.

6 July 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
ASA. A. Sokolova
A. A. Sokolova
AKA. A. Kudriavtseva
A. A. Kudriavtseva
NKN. V. Kostokova
N. V. Kostokova
MZM. P. Zaikina
M. P. Zaikina
ZGZ. A. Gebekova
Z. A. Gebekova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Aim: The aim of this meta-analysis and systematic review was to evaluate the possible connection between AF and VTE.Material and methods. Atrial fibrillation (AF) and atrial flutter (AFL) contribute to intra-atrial blood stasis which leads to thrombus formation with its embolization. There is some evidence that AF can be a risk factor for deep vein thrombosis (DVT) and pulmonary embolism (PE). The following databases were searched: PubMed (MEDLINE), EMBASE, Google Scholar, the Cochrane Central Register of Controlled Trials. The time frame for conducting a systematic literature search ranged from January 1, 1990 to November 1, 2021. The diagnosis of atrial fibrillation had to be confirmed by using ECG. The diagnosis of VTE could be made with Doppler imaging, ventilation/perfusion scan, CT angiography, venography, angiography or autopsy. Only the three studies with 102192 patients meeting the requirement were included in the meta-analysis.Results. The prevalence of DVT and PE were assessed using incidence rate ratios (IRR) method of the inverse variance random effects model and its 95% confidence interval (CI). The significant association between atrial fibrillation and pulmonary embolism was found (IRR, 4.18 95% Cl 1.958.98). Also there is obvious association between DVT and AF (IRR, 2.97 95% Cl 2.18-4.03).Conclusion. It can be concluded that the increased risk of developing VTE is associatedwith concomitant AF.

1 January 2023 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
VMVadim P. Mikhin
Vadim P. Mikhin
АГАнна Игоревна Гиндлер
Анна Игоревна Гиндлер
НЗНаталья Викторовна Заикина
Наталья Викторовна Заикина
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
ТНТамара Александровна Николенко
Тамара Александровна Николенко
MCMarina A. Chernyatina
Marina A. Chernyatina
Objective: to conduct a comparative assessment of the parameters of heart rhythm and conduction in patients with Covid-19 with acute ST-segment elevation myocardial infarction (STEMI) in the hospital and post-hospital treatment periods. Materials and methods. The study included 140 patients with STEMI, stratified into 2 groups: I - the main (52 people) patients with STEMI who had COVID-19 for 1.5-6 months before the development of acute coronary syndrome (ACS), II - the comparison group (88 people) with STEMI without COVID-19 in the anamnesis. All patients underwent percutaneous coronary intervention with stenting of a single infarct-related artery in the first 24 hours. Daily ECG monitoring was performed with an assessment of traditional heart rate and conduction parameters for 2-3 days, 9-11 days and after 6 months from the moment of the accident. Results. In the main group, in contrast to the control group, a shortening of the QT interval (7.7% vs. 0.0%), ventricular extrasystole (VES) of Lown grade IV A (25.0% vs. 7.9%) was more often recorded on 2-3 days. Supraventricular extrasystole (SVE; 92.0% vs. 65.4%), sinus arrhythmia (37.5% vs. 0.0%), supraventricular tachycardia (SVT; 7.9% vs. 0.0%) were more often recorded in group II on 2-3 days. During the hospital follow-up period, the retention of shortened QT (7.7% vs. 0.0%), predominance SVE (90.4% vs. 76.1%), sinus arrhythmia (48.1% vs. 29.5%), migration of the rhythm driver along the atria (15.3% vs. 0.0%), VES Lown grade IV A (9.6 % vs. 0.0%). In the control group, AV blockade of 1 deg. (15.9% vs. 3.8%), AV blockade of 2 deg. (4.5% vs. 0.0%), CA blockade (3.4% vs. 0.0%), QT prolongation (12.5% vs. 0.0%) were more often determined. By 6 months after STEMI, patients in the main group were more likely to have SVT (9.6% vs. 0.0%) and VES Lown grade IV A (7.6% vs. 0.0%). In the control group, AV blockade of 1 deg. (9.0% vs. 0.0%), CA blockade (3.4% vs. 0.0%) were registered. Conclusion. Patients with STEMI who had a history of COVID-19 and without COVID-19 had a multidirectional dynamics of heart rate and conduction parameters during the hospital and post-hospital follow-up periods. In patients who underwent COVID-19, there was a predominance of ventricular arrhythmias of high Lown gradations on 2-3 days of STEMI, an increase in supraventricular arrhythmias on days 9-11, an increase in supraventricular and ventricular arrhythmias of high Lown gradations and the absence of CA and AB disorders after 6 months. In the control group, there was a predominance of supraventricular and ventricular arrhythmias of low gradations according to Lown, a predominance of CA and AB conduction disorders on days 9-11 and 6 months after STEMI.

28 February 2025 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
МТМаксим Игоревич Ткачёв
Максим Игоревич Ткачёв
ВКВероника Валерьяновна Когай
Вероника Валерьяновна Когай
ЕТЕлизавета Сергеевна Табаченкова
Елизавета Сергеевна Табаченкова
AKAnna A. Kudryavceva
Anna A. Kudryavceva
АСАнастасия Андреевна Соколова
Анастасия Андреевна Соколова
HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.

26 September 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VMV. P. Mikhin
V. P. Mikhin
OOO. A. Osipova
O. A. Osipova
AGA. I. Gindler
A. I. Gindler
ABA. S. Brizhaneva
A. S. Brizhaneva
NZN. V. Zaikina
N. V. Zaikina
MCM. A. Chernyatina
M. A. Chernyatina
Aim. To compare heart rate variability parameters in patients after a coronavirus disease 2019 (COVID-19) with acute ST elevation myocardial infarction (STEMI) during the inhospital and post-hospital periods. Material and methods. A total of 140 patients with STEMI were divided into 2 groups: I — patients with STEMI who had COVID-19 (n=52) in the period of 1,5-6 months before acute coronary syndrome, II — comparison group (n=88), which included patients with STEMI without prior COVID-19. All patients underwent infarct-related artery stenting within the first 24 hours from the onset. Heart rate variability (HRV) parameters were determined for all patients on days 2-3 and days 9-11 and 6 months after the hospitalization for STEMI. Results. Patients in group I showed more pronounced changes in HRV indicators on days 2-3 of STEMI: RMSSD (root square of successive RR intervals) by 21% (p=0,026), variations (Var) (the difference between the minimum and maximum RR intervals) by 33% (p=0,013), VLF (total very low-frequency HRV) by 7% (p=0,009) were higher, and HF (highfrequency HRV) by 40% (p=0,003), pNN50% (ratio of the number of consecutive RR interval pairs differing by >50 ms to the total number of RR intervals) by 66% (p=0,038) were lower than in the control group, respectively. On days 9-11 of the disease in patients with a history of STEMI and COVID-19, in contrast to the control group, there was a more pronounced increase in the SDNN (standard deviation of RR intervals) by 46% (p=0,005), VLF by 42% (p=0,031), whereas in the control group there were an increase of only 22% (p=0,004) and 11% (p=0,022), respectively. The HF value in the main group increased by 25% (p=0,007), while in the control group it decreased by 19% (p=0,030). Six months after STEMI in the main group, the RMSSD decreased by 19% (p=0,009), Var by 16% (p=0,041), VLF by 30% (p=0,025), LF (low-frequency component HRV) by 11% (p=0,005), while the control group these parameters decreased by 20% (p=0,006), 21% (p=0,001), 9% (p=0,011), and 7% (p=0,016), respectively. Conclusion. In patients with STEMI and prior COVID-19, the initial HRV values differ from similar HRV parameters in patients with STEMI without prior COVID-19. In the hospital and post-hospital periods, the changes of HRV in patients with and without COVID-19 are multidirectional as follows: pronounced sympathetic hyperactivity predominates, and slower recovery of HRV in patients after COVID-19 predominates.

1 January 2023 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
VMVadim P. Mikhin
Vadim P. Mikhin
АГАнна Игоревна Гиндлер
Анна Игоревна Гиндлер
НЗНаталья Викторовна Заикина
Наталья Викторовна Заикина
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
ТНТамара Александровна Николенко
Тамара Александровна Николенко
АААнтон Михайлович Александров
Антон Михайлович Александров
Objective: to evaluate the features of central and intracardiac hemodynamics in patients with ST-segment elevation myocardial infarction (STEMI), who underwent COVID-19 during inpatient stay and 6 months after the development of STEMI. Materials and methods. 140 patients with STEMI were included in the study. The patients were randomized into 2 groups: I - main group - patients with STEMI who suffered COVID-19 (52 people) in the period from 1.5-6 months before the development of acute coronary syndrome (ACS), II - comparison group (88 people) which included patients with STEMI who did not have COVID-19 in the anamnesis. All patients underwent PCI with stenting of the infarct-related artery in the first 24 hours from the onset of ACS. The parameters of central and intracardiac hemodynamics in all patients were determined for 2-3 days (1st control point), 9-11 days (2nd control point), after 6 months (3rd control point) from the moment of hospitalization for STEMI. Results. In the patients of the main group of the study, more pronounced changes in the systolic-diastolic LV function were recorded on the 2-3 day of STEMI: LV EF by 8.5%, Sm by 7.2% and E' by 24.5% (p<0.05) were lower than in the control group, respectively, E/E' by 11.5% and WMSI by 21.8% (p<0.05) were higher than in the comparison group. On the 9th-11th day of the disease in patients with STEMI who underwent COVID-19, a slowdown in the recovery of the studied parameters was revealed: the LV EF value was lower than in the control group by 11%, Sm by 12% and E' by 20% (p<0.05), respectively, and the value of E/E' by 27% and WMSI by 25% (p<0.05) were higher than in the comparison group. 6 months after STEMI, there were no significant differences in Sm, E', E/E' values in the main and control groups, however, a lower LVEF and WMSI value was noted in comparison with the control group (p<0.05). Conclusion. Unidirectional positive dynamics of systolic-diastolic function parameters in hospital and post-hospital follow-up periods was observed in patients with STEMI, both those who had COVID-19 and without COVID-19 in the anamnesis. However, in patients who underwent COVID-19, there were more pronounced violations of LV systolic-diastolic function on 2-3 days and less pronounced, delayed positive dynamics of these parameters during the hospital and post-hospital treatment periods.